Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(14%)
Results Posted
75%(3 trials)

Phase Distribution

Ph phase_3
5
71%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 3Large-scale testing
5(83.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(4)
Other(1)

Detailed Status

Completed4
Active, not recruiting1
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 35 (83.3%)

Trials by Status

completed457%
active_not_recruiting114%
unknown114%
not_yet_recruiting114%

Recent Activity

1 active trials
Showing 5 of 7
active_not_recruitingphase_3

Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)

NCT07670546
not_yet_recruitingphase_3

Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease

NCT07625384
completedphase_1

Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

NCT04246762
completedphase_3

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

NCT02760368
completedphase_3

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07670546Phase 3

Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)

Active Not Recruiting
NCT07625384Phase 3

Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease

Not Yet Recruiting
NCT04246762Phase 1

Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

Completed
NCT02760368Phase 3

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Completed
NCT02760433Phase 3

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

Completed
NCT05187793Phase 3

Study of Efficacy of Different Treatment Regimens of Olokizumab

Unknown
NCT05196477

Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7